Glenmark Pharma
- All
- News
- Videos
-
15 Lakh Bottles Of ADHD Medication Recalled In U.S. By Glenmark
ADHD is seen as a chronic and incapacitating disorder that affects a person's everyday functioning.
-
Glenmark Pharma To Sell 75% Stake In Life Sciences To Nirma For $680 Million
Drugmaker Glenmark Pharmaceuticals said on Thursday it would sell a 75% stake in unit Glenmark Life Sciences to detergent maker Nirma for 56.52 billion rupees ($679.84 million).
-
Glenmark Pharmaceuticals Recalls 1,200 Bottles Of "Subpotent" Hypertension Drug In US
Glenmark Pharmaceuticals is recalling 1,200 bottles of a generic drug, used to treat high blood pressure, in the American market due to a manufacturing issue, according to the US Food and Drug Administration (USFDA).
-
Glenmark Pharmaceuticals Gets Final US Approval For Lacosamide Tablet
Homegrown pharma major Glenmark Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic Lacosamide tablet, indicated for prevention and control of seizures.
-
First Nasal Spray For Treating Adult Covid Patients Launched In India
Mumbai based innovation-driven global pharma company Glenmark has launched Nitric Oxide Nasal Spray (FabiSpray) in India, in partnership with SaNOtize, for treatment of adult patients suffering from COVID-19.
-
Glenmark Pharma Receives 7 Observations From US Regulator On Baddi Unit, Shares Fall
Glenmark Pharmaceuticals said the Baddi unit contributes approximately 10 per cent of the revenue of US sales.
-
Delhi High Court Restrains Glenmark from Business of Anti-Diabetes Drugs
In a relief for US drug major Merck Sharp and Dohme (MSD), Delhi High Court today restrained Indian firm Glenmark Pharmaceuticals from manufacturing and selling its anti-diabetes drugs Zita and Zita-Met, saying it has infringed patent of the American company.
-
15 Lakh Bottles Of ADHD Medication Recalled In U.S. By Glenmark
ADHD is seen as a chronic and incapacitating disorder that affects a person's everyday functioning.
-
Glenmark Pharma To Sell 75% Stake In Life Sciences To Nirma For $680 Million
Drugmaker Glenmark Pharmaceuticals said on Thursday it would sell a 75% stake in unit Glenmark Life Sciences to detergent maker Nirma for 56.52 billion rupees ($679.84 million).
-
Glenmark Pharmaceuticals Recalls 1,200 Bottles Of "Subpotent" Hypertension Drug In US
Glenmark Pharmaceuticals is recalling 1,200 bottles of a generic drug, used to treat high blood pressure, in the American market due to a manufacturing issue, according to the US Food and Drug Administration (USFDA).
-
Glenmark Pharmaceuticals Gets Final US Approval For Lacosamide Tablet
Homegrown pharma major Glenmark Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic Lacosamide tablet, indicated for prevention and control of seizures.
-
First Nasal Spray For Treating Adult Covid Patients Launched In India
Mumbai based innovation-driven global pharma company Glenmark has launched Nitric Oxide Nasal Spray (FabiSpray) in India, in partnership with SaNOtize, for treatment of adult patients suffering from COVID-19.
-
Glenmark Pharma Receives 7 Observations From US Regulator On Baddi Unit, Shares Fall
Glenmark Pharmaceuticals said the Baddi unit contributes approximately 10 per cent of the revenue of US sales.
-
Delhi High Court Restrains Glenmark from Business of Anti-Diabetes Drugs
In a relief for US drug major Merck Sharp and Dohme (MSD), Delhi High Court today restrained Indian firm Glenmark Pharmaceuticals from manufacturing and selling its anti-diabetes drugs Zita and Zita-Met, saying it has infringed patent of the American company.
